Hims & Hers Stock Plummets. The Wegovy Shortage Is Over. - Barron's
1. Hims & Hers stock plunged over 23% after FDA resolved weight-loss drug shortages. The news directly threatens demand for its compounded GLP-1 shots. 2. FDA confirmed availability of Ozempic, Wegovy, and semaglutide. Demand for non-FDA-approved alternatives like Hims’ offering may drop. 3. Investors reacted sharply to the end of shortages for Lilly’s Zepbound as well. This regulatory update impacts Hims by eroding its competitive niche.